Latest Breaking News On - Enriqueta felip - Page 2 : comparemela.com

European Commission approves Roche s Tecentriq SC, the EU s first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection. Last year, more than 38,000 people in the EU received .

United statesUnited kingdomGreat britainLevi garrawayEnriqueta felipRoche groupEuropean medicines agencyHead of global product developmentEuropean unionEuropean commissionChief medical officerGlobal productThoracic cancer unitHebron hospitalHalozyme therapeutic enhanzeDow jones sustainability indices

Roche cancer immunotherapy receives new EU approval

Roche cancer immunotherapy receives new EU approval
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

United kingdomGreat britainRoche tecentriqEnriqueta felipMarlon trottmann shutterstockLevi garrawayHead of global product developmentEuropean society for medical oncologyEuropean commissionMarlon trottmannEuropean societyMedical oncologyChief medical officerGlobal product developmentThoracic cancer unitHebron hospital

Neoadjuvant, Adjuvant, or Both? The Debate in NSCLC Rages On

The question of whether to give upfront immunochemotherapy in resectable non–small cell lung cancer, wait until after surgery, or give both remains a hot topic of debate.

Comunidad autonoma de catalunaUnited statesSvizzera italianaTony sk mokZofia piotrowskaEnriqueta felipSilke gillessenFederico cappuzzoRafal dziadziuszkoUniversity of gdanskDepartment of oncologyDepartment of medical oncologyEuropean society for medical oncologyHebron university hospitalHospital cancer centerDepartment of clinical oncology

GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) -October 23, 2023 at 08:28 am EDT

GALLANT-1: GB1211 Galectin-3 inhibitor plus atezolizumab for first line treatment in patients .

Comunidad autonoma de catalunaFrance generalIsrael generalRodryg ramlauAshfield medcommsEnriqueta felipEnric carcerenyZahir rajiwateEric pichonBiomarcadoresy medicinaLinda basseChemother pharmacolTariq sethiAlison mackinnonPia jensenBertil lindmark

BerGenBio ASA: Additional data on BerGenBio s selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting

BerGenBio ASA: Additional data on BerGenBio s selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomPrnewswire bergenbioJan lillebyEnriqueta felipOddbjorn straumeMartin olinHaukeland university hospital in bergenEuropean society of clinical oncologistsOslo stock exchangeHebron university hospitalEuropean societyClinical oncologistsAnnual meetingThoracic cancer unitMonday octoberBoard number